The ferric conundrum: which intravenous iron preparations are preferred for chronic kidney disease patients?

Aimee Hechanova; Pouria Mostafizi; Kiyan Rad; Ramin Tolouian

doi:10.34172/jnp.2022.17372

J Nephropathol. 2022;11(3): e17372.
doi: 10.34172/jnp.2022.17372

Scopus ID: 85134164826

Abstract View: 1373

PDF Download: 298

Editorial

The ferric conundrum: which intravenous iron preparations are preferred for chronic kidney disease patients?

Aimee Hechanova ¹ , Pouria Mostafizi ² , Kiyan Rad ³ , Ramin Tolouian ⁴^*

¹ Division of Nephrology, Paul L. Foster School of Medicine, Texas Tech University Health Science Center of El Paso, El Paso, Texas, USA
² Department of Physiology, College of Medicine, University of Arizona, Tucson, Arizona, USA
³ Department of Internal Medicine, Southern Arizona VA Health Care System and College of Medicine, University of Arizona, Tucson, Arizona, USA
⁴ Division of Nephrology, Southern Arizona VA Health Care System and College of Medicine, University of Arizona, Tucson, Arizona, USA

*Corresponding Author: Corresponding author: Ramin Tolouian, Email: , Email: tolouian@arizona.edu

Keywords: Iron deposition, Iron deficiency anemia, Renal failure, Chronic kidney disease, IV iron, Iron infusion, Iron formulation

Implication for health policy/practice/research/medical education:

It has been demonstrated that iron deposition in the kidney is a harbinger of poor prognosis, but it is not clear whether kidney failure/damage predisposes iron deposition, or iron deposition activates an oxidative cascade and causes kidney damage. Until this issue is clarified, it will be difficult to predict the risks or benefits of any iron infusion for chronic kidney disease.

Please cite this paper as: Hechanova A, Mostafizi P, Rad K, Tolouian R. The ferric conundrum: which intravenous iron preparations are preferred for chronic kidney disease patients? J Nephropathol. 2022;11(3):e17372. DOI: 10.34172/jnp.2022.17372.